NASDAQ : OKUR
OnKure Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 2.62 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 106.10M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 106.10M |
| Enterprise Value | -69.36M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 40.50M |
| Shares Outstanding | 40.50M |
| Shares Change (YoY) | +126.66% |
| Shares Change (QoQ) | +264.69% |
| Owned by Insiders (%) | 10.23% |
| Owned by Institutions (%) | 49.99% |
| Float | 18.68M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 181.88 |
| PB Ratio | 0.62 |
| P/TBV Ratio | 0.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 26.75 |
| Quick Ratio | 26.55 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7,767.50 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -46.91% |
| Return on Assets (ROA) | -29.26% |
| Return on Invested Capital (ROIC) | -30.82% |
| Return on Capital Employed (ROCE) | -35.98% |
| Weighted Average Cost of Capital (WACC) | 8.21% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.30M |
| Employee Count | 45 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.73 |
| 52-Week Price Change | -17.87% |
| 50-Day Moving Average | 2.91 |
| 200-Day Moving Average | 3.61 |
| Relative Strength Index (RSI) | 50.88 |
| Average Volume (20 Days) | 344,751 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.39M |
| Short Previous Month | 1.22M |
| Short % of Shares Out | 3.42% |
| Short % of Float | 7.42% |
| Short Ratio (days to cover) | 3.50 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -62.14M |
| Pretax Income | -58.71M |
| Net Income | -58.71M |
| EBITDA | -61.74M |
| EBIT | -62.14M |
| Earnings Per Share (EPS) | -$2.58 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 176.39M |
| Total Debt | 926,000 |
| Net Cash | 175.46M |
| Net Cash Per Share | $4.33 |
| Equity (Book Value) | 172.11M |
| Book Value Per Share | 4.25 |
| Working Capital | 171.03M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -47.84M |
| Capital Expenditures | -23,000 |
| Depreciation & Amortization | 403,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -47.86M |
| FCF Per Share | -$1.18 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -126.66% |
| Shareholder Yield | n/a |
| Earnings Yield | -98.63% |
| FCF Yield | -45.11% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $15.50 |
| Price Target Difference | 491.60% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |